GlassScriptPhysician profile
Catherine Mary Quinn
NPI 1427146315
$3,605.81
in general payments reported to CMS, 2019-2025
11 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $237 · 2024: $1,846 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,432 · Travel and Lodging: $1,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,431.83 |
| Travel and Lodging | $1,173.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,984.17 | 2024-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $576.70 | 2023-2025 | Airsupra, Breztri, Tezspire |
| Avadel Cns Pharmaceuticals, LLC | $260.91 | 2023-2025 | Lumryz |
| Jazz Pharmaceuticals INC. | $255.68 | 2024-2025 | |
| Lilly USA, LLC | $124.96 | 2025 | Zepbound |
| Phathom Pharmaceuticals, INC. | $119.92 | 2025 | Voquezna |
| United Therapeutics Corporation | $117.53 | 2025 | Tyvaso, Orenitram, Remodulin |
| Merck Sharp & Dohme LLC | $57.93 | 2025 | Winrevair |
| Axsome Therapeutics, INC. | $42.77 | 2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $37.20 | 2025 | Uptravi, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $28.04 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.